.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,965,581

« Back to Dashboard

Claims for Patent: 5,965,581

Title: Compositions for inhibiting platelet aggregation
Abstract:A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -[4-(4-(piperdin-4-yl)butyloxylphenyl]propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5.
Inventor(s): Gelotte; Karl M. (North Wales, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/079,776
Patent Claims: 1. A composition comprising about 0.25 mg/ml 2-S-(n-Butylsulonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propioni c acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg and pH is in the range of between 5.5-6.5.

2. A composition comprising about 0.05 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg and pH is in the range of between 5.5-6.5.

3. A composition formed by combining together about 0.28 mg/ml 2-S -(n-Butylsufonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic hydrochloride monohydrate, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, and about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg and pH is in the range of between 5.5-6.5.

4. A composition formed by combining together about 0.056 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic hydrochloride monohydrate, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, and about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg and pH is in the range of between 5.5-6.5.

5. A method for inhibiting the aggregation of blood platelets in a patient, comprising intravenously treating the patient with a pharmaceutically effective amount of the composition of claim 1.

6. A method for inhibiting the aggregation of blood platelets in a patient, comprising intravenously treating the patient with a pharmaceutically effective amount of the composition of claim 2.

7. A composition formed by combining together about 0.28 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl) butyloxy)phenyl]propionic acid hydrochloride monohydrate, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihdrate, and about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg, and composition pH, adjusted if necessary with one or more pH adjusting agents, is in the range of between 5.5-6.5.

8. A composition formed by combining together about 0.056 mg/ml 2-S-(n-Butysulfonylamino)-3[4-(4-(piperidin-4-yl)butyloxy)phenyl]propronic acid hydrochloride monohydrate, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, and about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg, and composition pH, adjusted if necessary with one or more pH adjusting agents, is in the range of between 5.5-6.5.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc